Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RAD51C R193* |
| Therapy | Cisplatin |
| Indication/Tumor Type | ovarian carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C R193* | ovarian carcinoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of an ovarian carcinoma cell line harboring RAD51C R193* in culture (PMID: 28588062). | 28588062 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28588062) | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | Full reference... |